TABLE 1.

Effect of TCDD on CD40L-Induced Proliferation of Human and Mouse B Cells

	Percentage of total viable cells
Treatment groups	Division 0	Division 1	Division 2	Division 3	Division 4	Division 5	Division 6
Human B cells
CD40L	24.7	18.3	27.1	18.5	5.65	1.27	0.56
CD40L + VH	24.7	16.9	28.1	19.8	5.09	1.19	0.4
CD40L + TCDD 1nM	23.6	21.1	32.2	15.4	3.11	0.59	0.21
CD40L + TCDD 3nM	22.9	18	31.2	18.6	3.95	0.93	0.3
CD40L + TCDD 10nM	23.6	18.8	31.4	17.7	3.59	0.71	0.22
CD40L + TCDD 30nM	22.7	19.7	32.1	17.1	3.51	0.72	0.25
Mouse B cells
CD40L	68.8	10.1	2.85	1.81	1.96	2.6	2.75
CD40L + VH	64.8	11.7	3.76	2.48	2.23	2.83	3.08
CD40L + TCDD 1nM	63.6	11.4	4.21	2.66	2.54	3.44	3.35
CD40L + TCDD 3nM	63.5	11.4	4.42	3.03	2.74	3.47	3.51
CD40L + TCDD 10nM	62.5	11.7	4.71	3.05	2.75	3.43	3.25
CD40L + TCDD 30nM	59.9	13.5	5.46	3.39	2.88	3.58	3.06

The experimental design was as described in the legend for Figure 11. Human or mouse B cells were treated with TCDD at concentrations indicated prior to activation by CD40L. The values are concatenated from three experimental replicates per treatment group. Human or mouse B cells (1 × 10⁶/ml) were labeled with the proliferation dye, treated with TCDD at concentrations indicated or VH, and then cocultured with irradiated CD40L-L cells (1.5 × 10³ cells per well for human and 5 × 10⁴ cells per well for mouse) in the presence of recombinant human or mouse IL-2 (10 U/ml), IL-6 (100 U/ml), and IL-10 (20 ng/ml) for 4 or 3 days, and CD40L stimulation was removed on day 4 or 3. Cells were cultured for one additional day prior to being harvested on day 5 or 4 to flow cytometric analysis. Dead cells were excluded from the analysis using the Live/Dead Near-Infrared Dead Cell Staining Kit. Data are representative of two separate experiments and are concatenated from three experimental replicates per group.